United Therapeutics presented its expanded fibrosis pipeline at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on Wednesday, laying out plans for up to 14 new product launches between 2027 and 2029 and projecting the company could grow into a $50 billion to $100 billion revenue pharmaceutical business by the early 2030s.
Nebulized Tyvaso is central to the near-term outlook. The company has been working toward approval and expects a PDUFA date of April 26, 2027 under a standard FDA review. Management said it is targeting 10,000 patients on the nebulized formulation in the first year of launch, which is currently planned for mid-2027.
On pricing, CFO James Edgemond said there is no anticipation of reimbursement changes for Tyvaso at this point. "We don't talk a lot about pricing forward," he said, adding that more detail would come closer to the April 26 decision date.
United Therapeutics also provided an update on the TETON-3 trial, which is evaluating nebulized Tyvaso in progressive pulmonary fibrosis. The study enrolled roughly 700 patients and is powered at 90% for an 80 ml improvement in forced vital capacity. Data from TETON-3 is expected in the second half of 2027.
Founder and CEO Martine Rothblatt described the TETON results as "by far the best results ever reported from any drug from any company in 30 years in pulmonary fibrosis." She noted that clinical trials saw discontinuation rates above 20%, often driven by disease progression or intolerance to older baseline treatments such as pirfenidone and nintedanib, where patient drop-offs outpaced those remaining on therapy by more than 3-to-1.
Further along the pipeline, the company plans to file for coughless TreSMI by the end of 2027. Once-daily inhaled ralinepag is targeted for 2028–2029 and carries patent protection through 2040. Enrollment for a clinical trial in COPD with pulmonary hypertension is expected to begin in 2027.
United Therapeutics framed the cumulative opportunity across its respiratory indications as roughly 1 million U.S. patients. Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis together account for approximately 400,000 U.S. patients, while COPD with pulmonary hypertension represents 400,000 to 800,000, according to management. The historical pulmonary hypertension market involves roughly 25,000 U.S. patients and has generated peak potential revenue of around $10 billion.
On the capital return front, United Therapeutics announced a $500 million accelerated stock repurchase agreement.
Shares closed at $506.82 on the day of the transcript, up 1.78% from a prior close of $497.97; the stock was later reported to have settled at $500.35 on September 15. The shares have traded between $395 and $609.35 over the past 52 weeks. The P/E ratio stood at 18.09, and analyst price targets ranged from $515 to $725.
For the trailing 12 months, United Therapeutics reported revenue of $3.15 billion and a gross profit margin of 86%.
